An impaired renal function and advanced heart failure represent independent predictors of the incidence of malignant ventricular arrhythmias in patients with an implantable cardioverter/defibrillator for primary prevention

Europace

Volumn 12, Issue 10, 2010, Pages 1439-1445

  Kreuz, Jens ^a   Balta, Osman ^a   Linhart, Markus ^a   Fimmers, Rolf ^a   Lickfett, Lars ^a   Mellert, Fritz ^a   Nickenig, Georg ^a   Schwab, Joerg Otto ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Advanced heart failure; Appropriate and inappropriate therapy; Implantable cardioverter defibrillator; Primary prevention; Risk stratification; Sudden cardiac death

Indexed keywords

CREATININE;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTATION; INDEPENDENT VARIABLE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ARRHYTHMIAS, CARDIAC; COHORT STUDIES; CREATININE; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; INCIDENCE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77957735444     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq283     Document Type: Article

References (18)

1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
2. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004;109:1082-4.
3. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML et al. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:1811-7.
4. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
6. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8.
7. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-17.
8. Kreuz J, Balta O, Liliegren N, Mellert F, Esmailzadeh B, Nickenig G et al. Incidence and Characteristics of Appropriate and Inappropriate Therapies in Recipients of ICD Implanted for Primary Prevention of Sudden Cardiac Death. PACE 2007;30: S1-S3.
9. Backenkohler U, Erdogan A, Steen-Mueller MK, Kuhlmann C, Most A, Schaefer C et al. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest. J Cardiovasc Electrophysiol 2005;16:478-82.
10. Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz LI et al. Renal insufficiency predicts the time to first appropriate defibrillator shock. Am Heart J 2006;151:852-6.
11. Amin MS, Fox AD, Kalahasty G, Shepard RK, Wood MA, Ellenbogen KA. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis. J Cardiovasc Electrophysiol 2008;19:1275-80.
12. Cuculich PS, Sánchez JM, Kerzner R, Greenberg SL, Sengupta J, Chen J et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007;30:207-13.
13. Morgan JM, Sterns LD, Hanson JL, Ousdigian KT, Otterness MF, Wilkoff BL. A trial design for evaluation of emperic programming of implantable cardioverter defibrillators to improve patient management. Curr Control Trials Cardiovasc Med 2004;5:12.
14. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverterdefibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006;48:330-9.
15. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006;295:165-71.
16. Wilkoff BL, Stern R, Williamson B, Wathen M, Holloman K, Fieberg A et al. Design of the primary prevention parameters evaluation (PREPARE) trial of implantable cardioverter defibrillators to reduce patients morbidity. Trials 2006;7:18.
17. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;52:541-50.
18. Schwab JO, Gasparini M, Lunati M, Proclemer A, Kaup B, Santi E et al. Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter/defibrillator: the ADVANCE III Trial. J Cardiovasc Electrophysiol 2009;20:663-6.